The US Food and Drug Administration on Wednesday approved Infilbray (venglustat) tablets as the first treatment for the neurological symptoms of Type 3 Gaucher disease, for adults and pediatric patients weighing at least 15 kilograms. The drug, approved to Genzyme Corporation, a Sanofi company, crosses the blood-brain barrier and works as a glucosylceramide synthase inhibitor, reducing the buildup of fatty substances in the body and the brain that drives the disease’s effects on balance, coordination, speech, memory and thinking. It was granted Orphan Drug designation and Priority Review.
The approval rests on a randomized, double-blind study of 43 patients aged 12 and older who had previously been treated with enzyme replacement therapy, in which patients taking Infilbray once daily showed improvement at 52 weeks on a combined measure of ataxia and cognitive function compared with those continuing enzyme replacement therapy. The agency said the most frequent side effects are gastrointestinal symptoms and effects on mood, and that serious psychiatric risks, including suicidal ideation and behavior, have been reported.